Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene.

Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA.

Menopause. 2005 Jul-Aug;12(4):444-52. Epub 2005 Jul 21.

PMID:
16037760
[PubMed - indexed for MEDLINE]
2.

Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.

Keech CA, Sashegyi A, Barrett-Connor E.

Curr Med Res Opin. 2005 Jan;21(1):135-40.

PMID:
15881485
[PubMed - indexed for MEDLINE]
3.
4.

Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.

Curr Med Res Opin. 2008 Mar;24(3):807-13. doi: 10.1185/030079908X273282. Epub 2008 Feb 5.

PMID:
18254988
[PubMed - indexed for MEDLINE]
5.
6.

Safety assessment of raloxifene over eight years in a clinical trial setting.

Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL.

Curr Med Res Opin. 2005 Sep;21(9):1441-52.

PMID:
16197663
[PubMed - indexed for MEDLINE]
7.

The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.

Gol M, Baris N, Guneri S, Posaci C.

Am J Obstet Gynecol. 2006 May;194(5):1249-54.

PMID:
16647907
[PubMed - indexed for MEDLINE]
8.

Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL.

J Fam Pract. 2004 Oct;53(10):789-96. Erratum in: J Fam Pract. 2005 Mar;54(3):276.

PMID:
15469774
[PubMed - indexed for MEDLINE]
9.

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR; CORE Investigators.

J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61.

PMID:
15572757
[PubMed - indexed for MEDLINE]
Free Article
10.

Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.

Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.

Clin Cancer Res. 2006 Sep 1;12(17):5242-7.

PMID:
16951244
[PubMed - indexed for MEDLINE]
Free Article
11.

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.

Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, Cummings S; Multiple Outcomes of Raloxifene Evaluation Investigators.

Obstet Gynecol. 2004 Oct;104(4):837-44.

PMID:
15458908
[PubMed - indexed for MEDLINE]
12.

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.

Ensrud K, Genazzani AR, Geiger MJ, McNabb M, Dowsett SA, Cox DA, Barrett-Connor E.

Am J Cardiol. 2006 Feb 15;97(4):520-7. Epub 2006 Jan 4.

PMID:
16461049
[PubMed - indexed for MEDLINE]
13.

Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.

Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr.

J Am Geriatr Soc. 2004 Sep;52(9):1543-8.

PMID:
15341559
[PubMed - indexed for MEDLINE]
14.

Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women.

Cox DA, Sarkar S, Harper K, Barrett-Connor E.

Curr Med Res Opin. 2004 Jul;20(7):1049-55.

PMID:
15265250
[PubMed - indexed for MEDLINE]
15.

Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.

Duvernoy CS, Yeo AA, Wong M, Cox DA, Kim HM.

J Womens Health (Larchmt). 2010 Aug;19(8):1459-65. doi: 10.1089/jwh.2009.1687.

PMID:
20626269
[PubMed - indexed for MEDLINE]
16.

Design and methods of the Raloxifene Use for The Heart (RUTH) study.

Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW.

Am J Cardiol. 2001 Aug 15;88(4):392-5.

PMID:
11545760
[PubMed - indexed for MEDLINE]
17.

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

McClung MR, Siris E, Cummings S, Bolognese M, Ettinger M, Moffett A, Emkey R, Day W, Somayaji V, Lee A.

Menopause. 2006 May-Jun;13(3):377-86.

PMID:
16735934
[PubMed - indexed for MEDLINE]
18.

Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.

Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR.

Menopause. 2010 Jan-Feb;17(1):57-63. doi: 10.1097/gme.0b013e3181b34749.

PMID:
19680161
[PubMed - indexed for MEDLINE]
19.

Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial.

Wenger NK, Barrett-Connor E, Collins P, Grady D, Kornitzer M, Mosca L, Sashegyi A, Baygani SK, Anderson PW, Moscarelli E.

Am J Cardiol. 2002 Dec 1;90(11):1204-10.

PMID:
12450599
[PubMed - indexed for MEDLINE]
20.

Carotid artery intima-media thickness after raloxifene treatment.

Mack WJ, Dhungana B, Dowsett SA, Keech CA, Feng M, Li Y, Hodis HN.

J Womens Health (Larchmt). 2007 Apr;16(3):370-8.

PMID:
17439382
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk